Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ01024 plus ruxolitinib in myelofibrosis
CTR20251050Phase 2Active
- Sponsor
- Junjing Bio
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WJ01024, ruxolitinib in myelofibrosis (MF), sponsored by Junjing Bio. Started Jul 2025; status: active.
02
Drugs
WJ01024ruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20251050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251050.